Hepatitis C
Human viral infection
Follow Hepatitis C on Notably News to receive short updates to your email — rarely!
We include updates on Sjögren syndrome, Non-Hodgkin lymphoma, Polyarteritis nodosa, Ribavirin, Sofosbuvir, Sofosbuvir/velpatasvir, Albinterferon, HONOReform, Penrose Inquiry, Daria Hazuda, A and Others v National Blood Authority and Another, Membranoproliferative glomerulonephritis, Indolent lymphoma, Miravirsen, Danoprevir, Ledipasvir ... and more.
| 2023 | The National Comprehensive Cancer Network included R-CHP with polatuzumab vedotin as a category 1 preferred first-line treatment regimen for diffuse large B-cell lymphoma (DLBCL). |
| 2016 | Epidemiological data collection concludes, revealing comprehensive statistics about NHL prevalence, showing around 694,704 people living with the disease during this period. |
| 2016 | End of epidemiological data collection period showing Non-Hodgkin lymphoma as the sixth most common cancer in the UK and eleventh most common cause of cancer death. |
| 2016 | End of epidemiological data collection period, revealing approximately 694,704 people living with Non-Hodgkin lymphoma in the United States. |
| 2015 | Global cases of non-Hodgkin lymphoma reached 4.3 million, with 231,400 deaths, representing a 5.4% mortality rate. |
| 2014 | Start of epidemiological data collection period for Non-Hodgkin lymphoma diagnoses in the United Kingdom, with an average of 13,900 people diagnosed yearly. |
| 2012 | Epidemiological data collection begins for non-Hodgkin lymphoma (NHL) incidence and mortality rates in the United States, tracking approximately 19.6 cases per 100,000 adults annually and 5.6 deaths per 100,000 adults per year. |
This contents of the box above is based on material from the Wikipedia article Non-Hodgkin lymphoma, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.